Compare · GERN vs JNJ
GERN vs JNJ
Side-by-side comparison of Geron Corporation (GERN) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GERN and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $609.12B, about 659.4x GERN ($923.8M).
- Over the past year, GERN is up 15.2% and JNJ is up 54.6% - JNJ leads by 39.4 points.
- JNJ has been more active in the news (10 items in the past 4 weeks vs 4 for GERN).
- JNJ has more recent analyst coverage (25 ratings vs 16 for GERN).
- Company
- Geron Corporation
- Johnson & Johnson
- Price
- $1.44+1.05%
- $253.01+1.39%
- Market cap
- $923.8M
- $609.12B
- 1M return
- +23.08%
- +7.55%
- 1Y return
- +15.20%
- +54.56%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 1996
- News (4w)
- 4
- 10
- Recent ratings
- 16
- 25
Geron Corporation
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest GERN
- Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman
- Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Geron Announces Appointment of Chinmaya Rath as Chief Business Officer
- Director Spiegel Robert J. was granted 6,103 shares, increasing direct ownership by 3% to 205,810 units (SEC Form 4)
- Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
- SEC Form 8-K filed by Geron Corporation
- SEC Form 4 filed by Director Spiegel Robert J.
- SEC Form 4 filed by Director Molineaux Susan
- SEC Form 4 filed by Director Mcdonald John F
Latest JNJ
- Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award
- DePuy Synthes Acquires Expanding Innovations™
- Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026
- Johnson & Johnson reports Q2 2026 results, raises 2026 outlook
- Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
- Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
- SEC Form 11-K filed by Johnson & Johnson
- SEC Form 11-K filed by Johnson & Johnson